Norway Savings Bank’s Idexx Laboratories IDXX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $2.59M | Buy |
4,919
+263
| +6% | +$148K | 1.09% | 31 |
|
|
2026
Q1 | $2.62M | Buy |
4,656
+25
| +0.5% | +$16K | 1.24% | 27 |
|
|
2025
Q4 | $3.13M | Buy |
4,631
+941
| +26% | +$641K | 1.45% | 21 |
|
|
2025
Q3 | $2.36M | Sell |
3,690
-42
| -1% | -$25.5K | 1.14% | 30 |
|
|
2025
Q2 | $2M | Buy |
3,732
+294
| +9% | +$141K | 1.03% | 34 |
|
|
2025
Q1 | $1.44M | Buy |
3,438
+131
| +4% | +$56.9K | 0.82% | 42 |
|
|
2024
Q4 | $1.37M | Sell |
3,307
-85
| -3% | -$37.3K | 0.76% | 45 |
|
|
2024
Q3 | $1.71M | Sell |
3,392
-53
| -2% | -$25.7K | 0.93% | 36 |
|
|
2024
Q2 | $1.68M | Sell |
3,445
-204
| -6% | -$102K | 0.96% | 33 |
|
|
2024
Q1 | $1.97M | Sell |
3,649
-76
| -2% | -$41.5K | 0.82% | 44 |
|
|
2023
Q4 | $2.07M | Buy |
3,725
+60
| +2% | +$28.2K | 0.92% | 38 |
|
|
2023
Q3 | $1.6M | Buy |
3,665
+30
| +0.8% | +$15K | 0.79% | 45 |
|
|
2023
Q2 | $1.83M | Buy |
3,635
+188
| +5% | +$90.1K | 1% | 32 |
|
|
2023
Q1 | $1.72M | Buy |
3,447
+60
| +2% | +$28.7K | 0.87% | 41 |
|
|
2022
Q4 | $1.38M | Buy |
3,387
+151
| +5% | +$58.6K | 0.7% | 52 |
|
|
2022
Q3 | $1.05M | Buy |
3,236
+700
| +28% | +$257K | 0.57% | 61 |
|
|
2022
Q2 | $889K | Buy |
2,536
+262
| +12% | +$107K | 0.46% | 71 |
|
|
2022
Q1 | $1.24M | Buy |
2,274
+167
| +8% | +$87.8K | 0.56% | 63 |
|
|
2021
Q4 | $1.39M | Buy |
2,107
+40
| +2% | +$25.1K | 0.61% | 57 |
|
|
2021
Q3 | $1.28M | Buy |
2,067
+38
| +2% | +$25.5K | 0.61% | 56 |
|
|
2021
Q2 | $1.28M | Buy |
2,029
+80
| +4% | +$44.2K | 0.62% | 53 |
|
|
2021
Q1 | $954K | Sell |
1,949
-86
| -4% | -$43.1K | 0.5% | 64 |
|
|
2020
Q4 | $1.02M | Buy |
2,035
+26
| +1% | +$11.6K | 0.58% | 58 |
|
|
2020
Q3 | $790K | Sell |
2,009
-25
| -1% | -$9.24K | 0.53% | 59 |
|
|
2020
Q2 | $672K | Buy |
2,034
+215
| +12% | +$62.3K | 0.49% | 61 |
|
|
2020
Q1 | $440K | Buy |
1,819
+239
| +15% | +$62.4K | 0.38% | 72 |
|
|
2019
Q4 | $413K | Buy |
1,580
+75
| +5% | +$19.8K | 0.3% | 80 |
|
|
2019
Q3 | $410K | Sell |
1,505
-15
| -1% | -$4.17K | 0.33% | 75 |
|
|
2019
Q2 | $418K | Sell |
1,520
-20
| -1% | -$4.93K | 0.36% | 70 |
|
|
2019
Q1 | $344K | Sell |
1,540
-50
| -3% | -$10.3K | 0.3% | 76 |
|
|
2018
Q4 | $296K | Sell |
1,590
-20
| -1% | -$4.1K | 0.29% | 73 |
|
|
2018
Q3 | $402K | Sell |
1,610
-410
| -20% | -$99.5K | 0.35% | 67 |
|
|
2018
Q2 | $441K | Sell |
2,020
-40
| -2% | -$8.24K | 0.4% | 61 |
|
|
2018
Q1 | $394K | Sell |
2,060
-45
| -2% | -$8.3K | 0.37% | 67 |
|
|
2017
Q4 | $329K | Sell |
2,105
-50
| -2% | -$7.87K | 0.31% | 72 |
|
|
2017
Q3 | $335K | Hold |
2,155
| – | – | 0.32% | 72 |
|
|
2017
Q2 | $348K | Sell |
2,155
-105
| -5% | -$17.1K | 0.34% | 71 |
|
|
2017
Q1 | $349K | Sell |
2,260
-2,850
| -56% | -$393K | 0.36% | 69 |
|
|
2016
Q4 | $599K | Buy |
+5,110
| New | +$583K | 0.56% | 57 |
|
Other funds holding IDXX
MBI
CGI
CAM
WF
RG
LWCFA
Norway Savings Bank's IDXX Position: Q2 2026 in Review
Norway Savings Bank increased its Idexx Laboratories (IDXX) stake by 5.6% in Q2 2026, buying an estimated $148K and bringing the position to 4,919 shares worth $2.59M. The position accounts for 1.09% of the portfolio, ranked #31.
Norway Savings Bank first reported a position in IDXX in Q4 2016 and has held it in 39 quarters since. The position peaked at $3.13M in Q4 2025. 509 funds tracked by Wall St. Rank hold IDXX as of Q2 2026.
- Norway Savings Bank held 4,919 shares of Idexx Laboratories worth $2.59M as of Q2 2026.
- Norway Savings Bank bought 263 Idexx Laboratories shares in Q2 2026, an estimated $148K.
- Idexx Laboratories made up 1.09% of Norway Savings Bank's portfolio in Q2 2026, its #31 holding.
- Norway Savings Bank first reported a position in Idexx Laboratories in Q4 2016 and has held it in 39 quarters since.
- Norway Savings Bank's Idexx Laboratories position peaked at $3.13M in Q4 2025.
- 509 funds tracked by Wall St. Rank held Idexx Laboratories as of Q2 2026.
Based on Norway Savings Bank's 13F filing for Q2 2026, filed 8 Jul 2026.